JPRN-UMIN000043734
Not yet recruiting
未知
A, randomized, controlled clinical trial to evaluate efficacy of EHL under cholangioscopy versus EPLBD including cost-effectiveness - A, randomized, controlled clinical trial to evaluate efficacy of EHL under cholangioscopy versus EPLBD including cost-effectiveness
ConditionsCommon bile duct stone
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Common bile duct stone
- Sponsor
- Osaka Medical College
- Enrollment
- 80
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Surgical altered anatomy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A randomized, controlled clinical trial to evaluate the efficacy of the digital Cognitive Behavioral Therapy somnio junior to reduce symptoms of insomnia in adolescens suffering from insomnia after three months of applicatioInsomnia (F51.0/G47.0) in adolescents (14-17 years)F51.0G47.0Nonorganic insomniaDisorders of initiating and maintaining sleep [insomnias]DRKS00033527mementor DE GmbH60
Not yet recruiting
Phase 3
A comparison of the safety and immune response profiles between the new Pfizer-BioNTech Omicron adapted COVID-19 vaccine and the original Pfizer-BioNTech COVID-19 vaccine in previously unvaccinated adults in East Africa.COVID-19PACTR202306533302513OXFORD580
Completed
Phase 3
A randomised, controlled clinical trial assessing the efficacy of;Lanreotide to halt disease progression in ADPKDAutosomal Dominant Polycystic Kidney Diseasepolycystic kidney disease100383601001965410029149NL-OMON39497niversitair Medisch Centrum Groningen300
Active, not recruiting
Not Applicable
To investigate the effect of Lanreotide on renal function decline in ADPKD patientsFirst, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.MedDRA version: 14.1Level: LLTClassification code 10023433Term: Kidney polycysticSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2011-005017-37-NLDIPAK Consortium
Recruiting
Not Applicable
Randomized, controlled, clinical trial for evaluation of the influence of platelet rich fibrin (PRF) in combination with bone substitute materials in use for regeneration of extraction socketsBone- and soft tissue regeneration after tooth extractionK08.1Loss of teeth due to accident, extraction or local periodontal diseaseDRKS00024023niversitätsklinikum der Goethe-Universität Frankfurt am Main Klinik für Mund-, Kiefer- und Plastische Gesichtschirurgie320